# Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: a modelling study

Source: https://onco.cc/key-papers/paper-kiendrebeogo-hpv-vaccination-cost-effectiveness-burkina-bmchsr-2023/  
OnCo record `paper-kiendrebeogo-hpv-vaccination-cost-effectiveness-burkina-bmchsr-2023` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Burkina Faso began vaccinating 9-year-old girls against HPV in 2022 with Gavi support. A model found vaccination could prevent 37% to 72% of cervical cancer cases and deaths and is cost-effective.

## Summary

A static cohort model of the impact and cost-effectiveness of HPV vaccination of 9-year-old girls in Burkina Faso over 2022 to 2031, comparing four vaccines with no vaccination, using local HPV type distribution, costs and coverage with GLOBOCAN 2020 burden data.

## Fields

- Kind: Key paper
- Last checked: 2026-11-11
- Journal: BMC Health Services Research
- Year: 2023
- DOI: 10.1186/s12913-023-10283-3
- Authors: Kiendrébéogo JA, Sidibe ARO, Compaoré GB, et al.
- Findings: Burkina Faso launched HPV vaccination for 9-year-old girls in 2022 with support from Gavi.; HPV vaccination could prevent 37% to 72% of cervical cancer cases and deaths.; Vaccination was cost-effective from a limited societal perspective; a single-dose strategy could improve cost-effectiveness further.
- What it means: It supports keeping the national HPV programme going after Gavi support.
- Caveats: A model; its results depend on assumed coverage, costs and efficacy.

## Sources

- DOI: https://doi.org/10.1186/s12913-023-10283-3
- PubMed: https://pubmed.ncbi.nlm.nih.gov/38041075/

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- institutions: [Ministère de la Santé, Burkina Faso](https://onco.cc/institutions/burkina-faso-ministry-of-health/)

---
JSON: https://onco.cc/api/v1/entities/paper-kiendrebeogo-hpv-vaccination-cost-effectiveness-burkina-bmchsr-2023.json